Innate Pharma (NASDAQ: IPHA) has presented data from a preliminary analysis of the TELLOMAK Phase 2 trial showing clinical activity and a favorable safety profile for lacutamab, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, in patients with advanced Sézary syndrome, a form of T cell lymphoma. The data was presented at the 2022 American Society Hematology Annual Meeting in New Orleans.

The company says that the global objective response rate in the ITT population was 21.6%, with ORR in the blood being 37.8%. In the EES population, global ORR was 22.9%, with ORR in the blood being 40.0%. Within the subgroup of patients that achieved a global response, median duration of global response was 10.8 months.

In the TELLOMAK Phase 2 trial, the company said that lacutamab showed a favorable safety profile for patients with advanced Sézary syndrome. The most common treatment-related adverse events were general disorders, skin and subcutaneous tissue disorders, and gastrointestinal disorders.

Dr. Joyson Karakunnel, MD, Chief Medical Officer of Innate Pharma, commented: “This encouraging preliminary analysis in Sézary syndrome adds to the encouraging cutaneous T-cell lymphoma data we previously shared within the Phase 1 study, and Phase 2 mycosis fungoides cohort. The data continues to support our fast to market strategy for lacutamab in the niche setting of Sézary syndrome where lacutamab was granted U.S. Fast Track designation and EU Prime designation. We look forward to final data in 2023 while we continue investigate the role of lacutamab in other T-cell lymphomas including the monotherapy and combination trials for peripheral T-cell lymphoma.”

During the ASH annual meeting, Pr. Vivier also gave an oral presentation on Innate Pharma's ANKETTM platform, which boosts the capacity of NK cells to proliferate, accumulate at the tumor site, and kill tumor cells.

ANKETTM is Innate Pharma's platform for developing multi-specific natural killer (NK) cell engagers to treat certain types of cancer. The platform leverages the advantages of harnessing NK cell effector functions against cancer cells and provides proliferation and activation signals targeted to NK cells. The latest innovation, the tetra-specific ANKET molecule, is the first NK cell engager technology to engage activating receptors, a tumor antigen, and an interleukin-2 receptor via a single molecule.

Shares of Innate Pharma trade on the NASDAQ under the ticker symbol IPHA. For more information visit www.innate-pharma.com.